Ruxolitinib cream + Vehicle cream

Phase 2Completed
0 watching 0 views this week Active
49
Hype Score

Development Stage

Pre-clinical
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Lichen Sclerosus

Conditions

Lichen Sclerosus

Trial Timeline

Nov 18, 2022 → Dec 21, 2023

About Ruxolitinib cream + Vehicle cream

Ruxolitinib cream + Vehicle cream is a phase 2 stage product being developed by Incyte for Lichen Sclerosus. The current trial status is completed. This product is registered under clinical trial identifier NCT05593445. Target conditions include Lichen Sclerosus.

Hype Score Breakdown

Clinical
17
Activity
12
Company
7
Novelty
5
Community
5

Clinical Trials (14)

NCT IDPhaseStatus
NCT06804811Phase 3Recruiting
NCT06959225Phase 3Recruiting
NCT06958211Phase 3Recruiting
NCT06548360Phase 3Recruiting
NCT06238817Phase 3Completed
NCT05764161Phase 3Completed
NCT05755438Phase 3Completed
NCT05635838Phase 2Completed
NCT05593432Phase 2Completed
NCT05593445Phase 2Completed
NCT04896385Phase 2Completed
NCT03745638Phase 3Completed
NCT03745651Phase 3Completed
NCT03099304Phase 2Completed

Competing Products

12 competing products in Lichen Sclerosus

See all competitors
ProductCompanyStageHype Score
LP-10 (Liposomal Tacrolimus)Lipella PharmaceuticalsPhase 2
44
Tacrolimus cream + Clobetasol creamAstellas PharmaPhase 2
52
Baricitinib 4 milligram Oral TabletEli LillyPhase 2
52
pimecrolimus and clobetasol + clobetasol 0.05% creamNovartisPhase 2
52
Pimecrolimus 1% creamNovartisPhase 2
52
secukinumab 300 mg Q4W + secukinumab 300 mg Q2WNovartisPhase 2
52
Apremilast + PlaceboAmgenPhase 2
51
DeucravacitinibBristol Myers SquibbPhase 2
51
Dupilumab + PlaceboSanofiPhase 3
76
Dupilumab + PlaceboSanofiPhase 3
76
Amevive (Alefacept) + PlaceboBiogenPhase 2
49
Ruxolitinib cream + Vehicle creamIncytePhase 2
49